Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
Rhea-AI Summary
Artelo Biosciences (Nasdaq: ARTL) reported that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering the intended commercial formulation of ART27.13, its peripherally selective cannabinoid agonist. The allowed claims cover compositions of ART27.13 dispersed in polyethylene glycol and are expected to extend patent protection for ART27.13 in the United States through 2041, supporting the company’s long-term intellectual property strategy.
ART27.13 is in two Phase 2 studies: the CAReS trial for cancer-related anorexia and the DREAM study in glaucoma or ocular hypertension. According to Artelo Biosciences, Phase 1 data showed good tolerability and early signs of stabilizing or reversing weight loss in over 60% of participants, while interim Phase 2 CAReS results showed reversal of cancer-related anorexia in all patients on the highest dose, with placebo patients continuing to lose weight. The DREAM Phase 2 study, funded by Glaucoma UK and the HSC R&D Division, is assessing once-daily oral ART27.13 to reduce intraocular pressure, with initial results anticipated in the fourth quarter of this year.
Positive
- Notice of Allowance for ART27.13 patent expected to extend U.S. protection through 2041
- Formulation coverage includes ART27.13 dispersed in polyethylene glycol, aligning with intended commercial product
- Phase 1 CAReS data showed ART27.13 was well tolerated with weight loss stabilized or reversed in over 60% of participants
- Interim Phase 2 CAReS results reported reversal of cancer-related anorexia in all patients on the highest dose vs continued weight loss on placebo
- Two concurrent Phase 2 programs in cancer-related anorexia and glaucoma/ocular hypertension diversify clinical opportunities
- DREAM Phase 2 study funding provided by Glaucoma UK and HSC R&D Division, reducing direct trial cost burden
Negative
- None.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 10 | Phase 2 enrollment | Positive | -2.2% | First patient dosed in the Phase 2 DREAM glaucoma study |
| Jun 10 | Metabolite data | Positive | -2.3% | Human metabolite findings supported continued ART26.12 clinical development |
| Mar 18 | Glaucoma study expansion | Positive | +50.7% | Fully funded investigator-sponsored glaucoma study expanded ART27.13 development |
| Mar 18 | Study agreement | Positive | +50.7% | Definitive agreement established ART27.13 glaucoma study collaboration |
| Oct 15 | Clinical data presentation | Positive | +1.4% | Expanded ART26.12 and ART27.13 data scheduled for summit presentation |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical-trial-tagged events showed mixed reactions: three aligned and two divergent, with an average move of 19.68%.
Key Terms
notice of allowance regulatory
polyethylene glycol technical
cannabinoid agonist medical
intraocular pressure medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Patent Claims are for the Intended Commercial Formulation of ART27.13
Expected to Extend Patent Protection for ART27.13 through 2041
SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a U.S. patent application covering the intended commercial formulation of ART27.13, the Company’s peripherally selective cannabinoid agonist currently being evaluated in the Phase 2 CAReS trial for cancer-related anorexia and the Phase 2 DREAM study in patients with glaucoma or ocular hypertension.
The allowed claims protect compositions of ART27.13 dispersed in polyethylene glycol, including the Company’s intended commercial formulation. This development marks a major milestone in Artelo’s global intellectual property strategy and positions the Company for long-term value creation.
“This U.S. Notice of Allowance and near-term expectation of the issuance of the patent further strengthens the intellectual property foundation supporting ART27.13 and its long-term development potential,” said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “As ART27.13 advances in multiple Phase 2 studies, we believe protecting the intended commercial formulation is an important step in building value around the program and preserving opportunities across multiple indications.”
ART27.13 is being evaluated in the Phase 2 portion of CAReS trial targeting cancer-related anorexia. The investigational drug was well tolerated in the Phase 1 stage and showed early signs of stabilizing or reversing weight loss in more than
ART27.13 is also being evaluated in the DREAM study, a Phase 2 in patients with glaucoma or ocular hypertension. The investigator-led study, funded by Glaucoma UK and the HSC R&D Division, is evaluating ART27.13's potential as a once-daily, orally administered treatment to reduce intraocular pressure, with initial results anticipated in the fourth quarter of this year.
About ART27.13
ART27.13 is a novel benzimidazole derivative and dual cannabinoid agonist. Initially developed by AstraZeneca plc, ART27.13 has been in seven clinical studies with over 280 participants. It is being developed as a once-daily, orally administered agent selectively targeting peripheral CB1 and CB2 receptors, with the potential to reduce muscle degeneration while improving body weight, appetite, and quality of life in cancer patients. A statistically significant and dose-dependent increase in body weight was observed in people with back pain who were otherwise healthy. Importantly, the drug enables systemic metabolic effects while minimizing central nervous system-mediated toxicity. Artelo is conducting a Phase 2 named the Cancer Appetite Recovery Study (CAReS) evaluating ART27.13 as a supportive care therapy for cancer patients suffering from anorexia and weight loss. Interim Phase 2 data revealed patients who had lost at least
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, commercial, and treasury management practices, including digital assets, to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
